JP3336000009
JP3336000009
SANTEN PHARMACEUTICAL CO
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2026 | 2025 | Change % |
|---|---|---|---|
| Total Revenue | 291.624.000.000 | 300.004.000.000 | 2.8% |
| Cost of Revenue | 121.881.000.000 | 128.977.000.000 | 5.5% |
| Gross Profit | 169.743.000.000 | 171.027.000.000 | 0.8% |
| 121.945.000.000 | 124.147.000.000 | 1.8% | |
| Operating Income | 47.798.000.000 | 46.880.000.000 | 2.0% |
| Pretax Income | 47.442.000.000 | 47.481.000.000 | 0.1% |
| Net Income Common Stockholders | 37.361.000.000 | 36.247.000.000 | 3.1% |
| -- | -- | -- | |
| -- | -- | -- |